Growth Drivers

  • Between 2011 and 2016, patent drugs worth USD 255 Billion are estimated to go off-patent leading to a huge surge in generic product and tremendous opportunities for companies.
  • By 2020, it will grow to USD 11 billion - a CAGR of 18%, with the potential to reach USD 13 billion - at an aggresive CAGR of 20%.
  • With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available.
  • Pharma companies have increased spending to tap rural markets and develop better infrastructure. The market share of hospitals is expected to increase from 13.1% in 2009 to 26% in 2020.
  • Following the introduction of product patents, several multinational companies are expected to launch patented drugs in India.
  • The purported rise of lifestyle diseases in India is expected to boost industry sales figures.
  • Over USD 200 Billion is to be spent on medical infrastructure in the next decade.
  • Rising levels of education are set to increase the acceptability of pharmaceuticals.
  • India’s patient pool is expected to increase to over 20% in the next 10 years, mainly due to the rise in population.

Reasons to Invest

  • India is expected to rank amongst the top three pharmaceutical markets in terms of incremental growth by 2020.
  • India will become the sixth largest market globally in terms of absolute size by zero.
  • India’s generic drugs account for 20% of global exports in terms of volume, making the country the largest provider of generic medicines globally.
  • India’s cost of production is significantly lower than that of the USA and almost half of that of Europe.
  • A skilled workforce as well as high managerial and technical competence.
  • Economic prosperity is likely to improve affordability for generic drugs in the market.
  • Approval time for new facilities has been drastically reduced.

Foreign investors